FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer

The approval is based on phase 3 trial data showing prolonged event-free survival with the pembrolizumab regimen vs neoadjuvant chemotherapy alone for previously untreated stage II or III TNBC.
FDA Approvals